Filing Details

Accession Number:
0001735276-23-000044
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-04-28 17:54:06
Reporting Period:
2023-04-26
Accepted Time:
2023-04-28 17:54:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178670 Alnylam Pharmaceuticals Inc. ALNY Pharmaceutical Preparations (2834) 770602661
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1829252 Pushkal Garg 675 West Kendall Street
Henri A. Termeer Square
Cambridge MA 02142
Cmo & Evp Dev & Med Affairs No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-04-26 4,294 $0.00 8,639 No 4 A Direct
Common Stock Disposition 2023-04-27 151 $193.18 8,488 No 4 S Direct
Common Stock Disposition 2023-04-27 700 $193.93 7,788 No 4 S Direct
Common Stock Disposition 2023-04-27 779 $194.94 7,009 No 4 S Direct
Common Stock Disposition 2023-04-27 80 $195.65 6,929 No 4 S Direct
Common Stock Disposition 2023-04-27 129 $197.08 6,800 No 4 S Direct
Common Stock Disposition 2023-04-28 204 $195.46 6,596 No 4 S Direct
Common Stock Disposition 2023-04-28 103 $196.62 6,493 No 4 S Direct
Common Stock Disposition 2023-04-28 715 $198.03 5,778 No 4 S Direct
Common Stock Disposition 2023-04-28 385 $199.54 5,393 No 4 S Direct
Common Stock Disposition 2023-04-28 955 $200.35 4,438 No 4 S Direct
Common Stock Disposition 2023-04-28 93 $201.30 4,345 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 431 Indirect by Managed Account
Common Stock 250 Indirect by Trust
Footnotes
  1. On February 23, 2022, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2021 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of human proof-of-concept of an investigational therapeutic directed to an extrahepatic target (central nervous system, or CNS).
  2. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
  3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 192.47 to $193.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 193.48 to $194.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 194.49 to $195.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  6. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 195.50 to $196.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  7. These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022.
  8. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 194.80 to $195.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  9. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 196.31 to $196.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  10. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 197.57 to $198.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  11. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 198.89 to $199.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  12. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 199.90 to $200.82. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  13. Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
  14. Represents shares held in trust, of which the reporting persons spouse is co-trustee. The reporting person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.